Filing Details

Accession Number:
0001595585-19-000009
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-08 16:34:47
Reporting Period:
2019-01-07
Accepted Time:
2019-01-08 16:34:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595585 Tricida Inc. TCDA Pharmaceutical Preparations (2834) 463372526
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1748808 Parsell Dawn Otto 7000 Shoreline Court, Suite 201
South San Francisco CA 94080
Sr Vp, Clinical Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-01-07 665 $23.27 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2018.
  2. This amount includes 665 shares acquired on December 31, 2018 under the Tricida, Inc. 2018 Employee Stock Purchase Plan. This acquisition is exempt from Section 16(b) pursuant to Rule 16b-3(c) and exempt from Section 16(a) pursuant to Rule 16a-3(f)(1)(i)(B).
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.22 to $23.425, inclusive. The reporting person undertakes to provide to Tricida, Inc., any security holder of Tricida, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.